Kornimate/medical-research-clean huggingface dataset:
mechanisms of walking recovery after stroke

Conditions: Stroke

Summary: subjects with stroke will have behavioral testing and brain imaging before and after a 4-week control period and a 4-week exercise intervention.

subjects with stroke will have behavioral testing and brain imaging before and after a 4-week control period and a 4-week exercise intervention using high-intensity interval training.

Eligibility criteria:
inclusion criteria: * age 30-90 years * unilateral stroke experienced \>6 months prior to enrollment in middle cerebral artery (mca) territory without complete disruption of the putamen on the lesion side * walking speed \<= 1.0 m/s on the 10 meter walk test * able to walk 10m over ground with assistive devices as needed and no physical assistance exclusion criteria: * mri incompatibility (e.g. metallic or electronic implants, severe claustrophobia) * inability to perform mental imagery (time dependent motor imagery screening test \[tdmi\]) * evidence of significant arrhythmia or myocardial ischemia on treadmill ecg stress test, or significant baseline ecg abnormalities that would make an exercise ecg uninterpretable * recent (\<3 months) cardiopulmonary hospitalization * unable to communicate with investigators or correctly answer consent comprehension questions * significant ataxia or neglect (score of 2 on nih stroke scale item 7 or 11) * severe lower extremity (le) spasticity (ashworth \>2) * recent (\<3 months) illicit drug or alcohol abuse or significant mental illness * major post-stroke depression (phq-9 ≥10) in the absence of medical management * participating in physical therapy or another interventional research study; * recent (\<3 months) paretic le botulinum toxin injection * concurrent progressive neurologic disorder or other major medical, orthopedic or peripheral vascular conditions that would limit improvement * pregnancy
morbidity and mortality follow up for the scleroderma lung study

Conditions: Scleroderma

Summary: the primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. while lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. for this reason, the investigators are following participants of the scleroderma lung study (nct00004563) after their participation in that study was concluded. in addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the scleroderma lung study experienced progression of their scleroderma-related lung disease following the end of the study.

retrospective and prospective data will be collected about patients who participated in the scleroderma lung study (sls). an attempt will be made to include all of the participants of the scleroderma lung study, who were reported as alive at the end of that study. a total of 158 subjects (79 per treatment arm) were randomized on the original scleroderma lung study. of those, 109 subjects completed the study. a single telephone interview with the participants to assess the occurrence of severe events and a review of the participant's medical records may be conducted. the outcome information will be combined with information collected about all participants in the sls study. the data being collected includes information on mortality, development of cancers, development of organ failure, and performance status.

Eligibility criteria:
inclusion criteria: * participation in the scleroderma lung study

Keywords: scleroderma interstitial lung disease
prospective cohort study of breast cancer patients treated with radiotherapy

Conditions: Breast Cancer

Summary: breast cancer occurred 19,219cases in 2015 and is the second most common cancer among female cancers in the country. despite there's been a disease understanding and treatment developing through study, the prevalence and mortality of breast cancer have increased steadily over the last 15 years. in the last 20 years, through random clinical studies of breast cancer, radiation therapy is well-established standard therapy as postoperative supplement of invasive breast cancer and intraepithelial carcinoma but, the need for further study with new questions about radiation therapy has been raised through these studies. according to the prospective study outcome, the radiation treatment of the regional lymph node in breast cancer patients with lymph node positive increases the free-disease survival rate, radiation therapy for regional lymph node is being actively treated than in the past. on the contrary, the results of another study are being reported that treating regional lymph node may increase the risk of arm edema, radiation pneumonia and heart toxicity. in the recently, due to advancement in radiation therapy technique, the implement of new radiation therapy such as imrt that reducing radiation dose to normal tissues of the axillary, lungs, heart and others has been actively attempted. additional research is needed on dose-fractionation schedule, regional lymph node treatment, post-treatment toxicity of radiation therapy in breast cancer. this study establishes a prospective cohort at breast cancer patients with radiation treatment and analyze the local and regional lymph node control, recurrence, toxicity, radiation planning, clinical data, discover the factors that predict local control, regional control, overall survival, recurrence-free survival, toxicity for treatment, so we intend to construct basic data that establishes a radiation treatment strategy based on comprehensive outcomes and predictors.


Eligibility criteria:
inclusion criteria: * scheduled to be a radiotherapy at national cancer center * agreed to participate in the study exclusion criteria: - disagreed to participate in the study
medial border of laparoscopic d3 lymphadenectomy for right colon cancer

Conditions: Colon Cancer

Summary: this study investigats the gastrointestinal functional outcomes of laparoscopic d3 lymphadenectomy for right colon cancer with the medial border along the left side of superior mesenteric artery (sma) versus the left side of superior mesenteric vein (smv). this is a single center, prospective cohort study with a sample size of 264 patients. the primary endpoint is the incidence of diarrhea (evaluated using the diarrhea assessment scale) one month after surgery.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * american society of anesthesiologists (asa) score i to iii * a biopsy proven histological diagnosis of colorectal carcinoma * tumor located at right half of colon * undergoing laparoscopic right hemi-colectomy * preoperative staging ct2-4an0m0 or ctanyn+m0 * willing to participate and informed consent signed exclusion criteria: * pregnant or lactating women * synchronous colorectal carcinoma * history of colorectal cancer or other malignant tumors * clinical evidence of metastasis * preoperative staging ct1n0 or ct4bnany * emergency procedure
follow-up study of the effectiveness of virtual reality therapy in patients with stroke

Conditions: Stroke

Summary: high intensity motion improves motor functions and quality of life in a neurologist. the investigators want to improve the clinical condition and quality of life of post-stroke participants with a special sensory motor and visual motor agility therapy. high intensity motion improves engine function and quality of life in a neurologist. with special sensory motor and visual motility, investigaters want to improve the clinical condition and quality of life of stroke participants. the investigaters randomly select participants who only perform the rehabilitation treatment have performed. the other group that will receive the study's control group will receive the traditional rehabilitation physiotherapy treatment. the investigaters assess the condition and quality of life of the patients. (eq5-d, barthel index, mrs test) the ivestigaters examine the functional movement and equilibrium variables of patients. (6mwt, berg balance test, postgraduation) after that, participants are undergoing a 4-week intensive rehabilitation treatment. all participants are in post stroke. primary hypothesis will be changes in life-quality tests (eq5-d, barthel index, mrs test). functional tests show progress 6mwt, berg balance test and postural control testing with posturography. the results are compared and evaluated among the groups. the expected hypothesis is that visual and acoustic stimulation produces a better physical state at higher intensity. patients were followed for 2 years and participated in a follow-up study every six months.


Eligibility criteria:
inclusion criteria: • post stroke exclusion criteria: * sever heart problem * sever demeanor * alcoholism * drug problems

Keywords: balance movement exergaming posture quality of life gait
psma and c-11 choline pet in patients with biochemical recurrence of prostate cancer

Conditions: Prostate Cancer

Summary: imaging and staging of prostate cancer is critical for surgical and treatment planning. in this protocol we will image patients with suspected metastatic prostate cancer using 11c-choline pet and gallium-68 labeled hbed-cc psma (more commonly called 68ga-psma-11) or f-18 labeled psma 1007 in order to demonstrate their utility in detecting prostate cancer.


Eligibility criteria:
inclusion criteria: 1. histopathological proven prostate adenocarcinoma. 2. rising psa after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy). a. post radical prostatectomy (rp) - with or without radiation. i. psa greater than or equal to 0.2 ng/ml measured more than 12 weeks after rp. ii. \> 3 months post-surgery b. post-radiation therapy astro-phoenix consensus definition c. may or may not be castrate resistant (list prior therapies) 3. karnofsky performance status of 50 (or ecog/who equivalent). 4. ct or as part of the pet study or performed within one month of psma pet. 5. age \> 18. 6. ability to understand a written informed consent document, and the willingness to sign it. exclusion criteria: 1. undergoing investigational therapy for prostate cancer. 2. other ongoing treatments for prostate cancer including radiation therapy, chemotherapy or androgen deprivation. androgen deprivation within the last 4 months excluding finasteride, dutasteride or other 5 alpha reductase inhibitors (excluding castrate resistant subjects). 3. unable to lie flat, still or tolerate a pet scan. 4. prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer. 5. contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (note: this exclusion criteria can be removed if furosemide is omitted as part of the pet imaging protocol if a second-generation scatter correction is available for the used pet device). 6. absence of psa and total testosterone tests within 4 weeks.

Keywords: prostate cancer pet/ct psma c-11 choline
management of ductal carcinoma in situ or pure micro-invasive extended breast

Conditions: Intraductal Carcinoma and Lobular Carcinoma in Situ

Summary: the rate of axillary dissection avoided in patients with ductal carcinoma in situ (dcis) and a mastectomy indication will be obtained by calculating the proportion of women with gas in-patient population that will prove to be dcis or dcis-mi + cci. a confidence interval of 95% will be deferred.

the rate of axillary dissection avoided in patients with dcis and a mastectomy indication will be obtained by calculating the proportion of women with gas in-patient population that will prove to be dcis or dcis-mi + cci (after the final histology). a confidence interval of 95% will be deferred (binomial). the rate of axillary dissection avoided in patients with dcis-mi and an indication of mastectomy is obtained by calculating the proportion of women with a gas-all women with dcis-mi and an indication of mastectomy. a confidence interval of 95% will be deferred (binomial).

Eligibility criteria:
inclusion criteria: * older than 18 years. * preoperative histological diagnosis obtained by biopsy * ductal carcinoma in situ (dcis) or pure micro-invasive (dcis-mi) * indication of mastectomy * patient signed informed consent exclusion criteria: * age \< 18 years * infiltrating ductal carcinoma (tcc) diagnosed on biopsy * pure dcis diagnosed by lumpectomy * dcis can take a conservative treatment * mastectomy chosen by the patient * history of breast carcinoma in situ or invasive ipsilateral * prior radiotherapy to the ipsilateral breast * history of axillary lateral homo * patient who for reasons psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study * patient deprived of liberty or under guardianship

Keywords: breast cancer
a study to compare the safety and efficacy of a new eye drop formulation with optive™ in subjects with dry eye disease

Conditions: Dry Eye Disease

Summary: this study will evaluate the safety and efficacy of a carboxymethylcellulose based eye drop formulation compared with carboxymethylcellulose based preservative-free lubricant eye drops (optive™) in subjects with dry eye disease.


Eligibility criteria:
inclusion criteria: * have used artificial tears for dry eye exclusion criteria: * start date of over the counter, herbal, prescription or nutritional supplements that may affect dry eye or vision within 3 months prior to study start or an anticipated change in dosage during the study * history of eye surgery or trauma in the 6 months prior to study start * current use or use within 2 weeks of study start, of topical eye medications.
15-day sequential therapy for helicobacter pylori infection in korea

Conditions: Helicobacter Pylori Infection

Summary: 10-day sequential therapy was not sufficient to overcome tough situation for h. pylori eradication in korea due to high antimicrobial resistance. the present investigators assumed that doubling duration of second phase of sequential therapy might have more potent bactericidal efficacy than previous 10-day sequential regimen. but 15-day regimen with initial 5-day ppi with amoxicillin followed by remaining 10-day ppi, clarithromycin with metronidazole was not ever tested before. moreover, whether extending the sequential therapy to 15-day might be more effective than 10-day sequential therapy is unknown especially in korea. from this background, the present investigators prepared clinical trials regarding modified sequential therapy which was extending the treatment duration to 15 days compared than previous 10-day sequential therapy regimen. in addition, pre-treatment antimicrobial susceptibility testing was performed to find the possibility to overcome antimicrobial resistance.


Eligibility criteria:
inclusion criteria: * patients with h. pylori infection who had never received treatment for h. pylori infection * h. pylori infection defined by a positive rapid urease test (clotest, delta west, bentley, australia) by gastric mucosal biopsy from the lesser curvature of the mid antrum or mid body or histological evidence of h. pylori by modified giemsa staining in the lesser and greater curvature of the mid antrum or mid body, respectively or a positive c-urea breath test. exclusion criteria: * patients with concurrent critical illness, a history of previous upper gastrointestinal surgery, contraindication to any of the study medications, recent frequent intake of nsaids, anticoagulants or steroids, an allergy to the study medications, and those that were pregnant or breast-feeding women were excluded from the study. other exclusion criteria include recent use of antimicrobials and any condition probably associated with poor compliance such as drug abusers or alcoholics.
effect of an experimental gel containing copaiba oil-resin in the control of dentin hypersensitivity

Conditions: Pain; Dentin Sensitivity; Dentin Desensitizing Agents

Summary: this randomized, single-blind, placebo-controlled clinical trial aims to clinically evaluate the effect of an experimental gel containing copaiba oleo-resin in the control of dentin hypersensitivity (dh) in non-carious cervical lesions (nccl). seventy-five hypersensitive teeth will be selected into three groups (n=25) and approved in three treatment sessions. the groups will be: group p= water-soluble placebo gel without active ingredient; group kf2: potassium nitrate 5% + sodium fluoride 2%; group gc: gel containing copaiba oleo-resin. a visual analogue scale (vas) will be used to compare the dh after tactile stimulation with an exploratory probe and evaporative stimulation with air jets. the dh assessments will be performed at four times: baseline, after 1 week, 15 days and 30 days after the beginning of treatment.

the sequence of application of the gels, whether active or placebo, will be as follows: a professional prophylaxis will be performed using a rubber cup on the dental elements. the corresponding gel for each group will be applied with the aid of a micro-applicator and will remain undisturbed on the surface for 10 minutes. after the gel application time has elapsed, and while it is still on the teeth, the product will be rubbed with a micro-applicator using circular and intermittent movements. subsequently, the gel will be removed with cotton and abundant water.

Eligibility criteria:
inclusion criteria: * hypersensitive areas on the vestibular surface of the teeth with exposed cervical dentin up to 1 mm deep and/or class i gingival recession according to the miller classification; * individuals who have at least two hypersensitive teeth * periodontal health, * good general physical health; * willingness to participate in the research by providing written informed consent; * no eating disorders or very acidic diets exclusion criteria: * presence of restorations; * presence of dental caries and periodontal pockets; * ongoing treatment with antibiotics and/or anti-inflammatory and/or analgesic drugs; * professional desensitizing treatment received three months prior to the study; * pregnancy or lactation; systemic diseases; * pulpitis; * use of orthodontic appliances or dental prostheses that may interfere with the assessment of hypersensitivity
safety study of olanzapine and a comparator in patients with schizophrenia and schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.


Eligibility criteria:
inclusion criteria: * 18-65 years old * diagnosed with schizophrenia or schizoaffective disorder * ability to visit the doctor's office for scheduled visits exclusion criteria: * women who are pregnant or breastfeeding * have a body mass index (bmi) greater than 40 * have diabetes, heart disease or any other unstable illness * have known positive human immunodeficiency virus (hiv) * are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics
noninvasive brain stimulation in adult amblyopia

Conditions: Amblyopia

Summary: the goal of this randomized controlled trial is to investigate the effectiveness of non-invasive brain stimulation in treating adults with amblyopia. the main questions it aims to answer are: 1. what are the effects of non-invasive brain stimulation on neuronal plasticity in the visual cortex of adults with amblyopia, and does it produce lasting changes? 2. do cumulative sessions of non-invasive brain stimulation influence neural plasticity and higher-order visual functions in adults with amblyopia? the investigators hypothesize that non-invasive brain stimulation will show a positive cumulative effect after five (5) consecutive days of stimulation on visual perception and function in adults with amblyopia. participants will be randomized into one of two treatment groups: 1. high-frequency transcranial random noise stimulation (hf-trns). 2. sham stimulation. researchers will compare baseline measurements of crowded visual acuity, contrast sensitivity, stereoacuity, phosphene thresholds, global motion perception, form pattern recognition and pattern-reversal visual evoked potentials (veps) to post-treatment measurements for each group.


Eligibility criteria:
inclusion criteria: * adults between 18 and 55 years of age * formal diagnosis of amblyopia in one or both eyes of any etiology exclusion criteria: * history of optic nerve disease, including glaucoma and optic neuritis * history of neurological conditions, including demyelinating disease or stroke * presence of metal or electronic implants in or on the body, including pacemakers * taking medications that can affect normal neurological function, including antipsychotics, antiepileptics, and opioids

Keywords: amblyopia non-invasive brain stimulation transcranial random noise stimulation visual perception visual evoked potentials
lithotripsy for the treatment of gallstones

Conditions: Cholelithiasis

Summary: the purpose of this study is to determine the effectiveness and safety of using the medstone lithotripter to treat single non-calcified gallstones from 4 to 20 mm in diameter.

this study is a randomized, single-masked controlled trial in which the combination therapy of lithotripsy and the bile acid drug actigall is compared to monotherapy with only actigall. the primary objectives are, 1) to determine whether the use of the medstone sts lithotripter system in combination with the orally administered drug actigall is more effective (as measured by percentages of stone free patients 6 months after randomization) in reducing single non-calcified radiolucent gallstones (from 4 to 20mm in diameter) than use of actigall alone, and 2) to demonstrate that use of the medstone lithotripsy system is safe (as measured by incidence of adverse events) for the intended purpose, when operated according to its labeling.

Eligibility criteria:
* history of biliary pain * evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (inclusive) diameter * hida scan demonstrating patency of cystic bile duct * no cardiac pacemaker * no allergy to radioopaque dye, iodine, bile acids * no spontaneous or iatrogenic bleeding disorder * no current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis * not pregnant

Keywords: gallstones gallstone biliary stones gallbladder stones gallbladder lithotripsy cholelithiasis eswl shock wave shock waves shockwaves shockwave
financial coaching and lifestyle intervention for diabetes prevention in low-income families

Conditions: Weight Loss

Summary: the purpose of this study is to compare the effect on weight and metabolic outcomes of an enhanced intervention, comprised of evidence-based financial coaching plus a lifestyle intervention vs. the lifestyle intervention alone


Eligibility criteria:
inclusion criteria: * english speaking parents * bmi\>25.0 at baseline * must have a child participant in the brighter bites program at study enrollment * own a smartphone (android 6 and iphone 12.4 or later) * must able to participate in study activities exclusion criteria: * medications known to affect appetite or body composition (e.g., corticosteroids, antidepressants, beta blockers, sulfonylureas, insulin) * currently diagnosed with conditions known to affect body composition or fat distribution (e.g., cushing's syndrome, hypothyroidism) * diagnosis of an eating disorder * currently pregnant.

Keywords: weight loss financial coaching cognitive functioning metabolic functioning psychosocial measures health behaviors